Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reza Malek

Vascular & Interventional Radiology Mountain View, CA Medical Doctor

NPI 1891739348 CMS profile 358714

701 E El Camino Real Fl 3, Mountain View, CA 94040

Open in the dashboard

General payments

$3,372

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,450 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Reza Malek of Mountain View, CA is reported in the CMS Open Payments database as having received $3,372 across 56 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,450 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 55th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $187 3
2024 General $975 12
2023 General $335 9
2022 General $618 8
2021 General $402 12
2020 General $70 4
2019 General $784 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reza Malek
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Reza Malek were reported at $187. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Reza Malek Vascular & Interventional Radiology median Middle half National median
2019 $784 $422 $125–$1,555 $163
2020 $70 $200 $68–$652 $114
2021 $402 $280 $99–$866 $132
2022 $618 $433 $137–$1,497 $149
2023 $335 $506 $152–$2,019 $160
2024 $975 $556 $175–$1,930 $164
2025 $187 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $584 4 payments
  2. Medical Device Business Services, Inc. $500 1 payment
  3. Medtronic, Inc. $425 12 payments
  4. Stryker Corporation $403 7 payments
  5. Penumbra, Inc. $227 5 payments
  6. AngioDynamics, Inc. $186 2 payments
  7. DePuy Synthes Sales Inc. $182 4 payments
  8. Siemens Medical Solutions USA, Inc. $170 1 payment
  9. Okami Medical, Inc. $148 1 payment
  10. Cardiva Medical, Inc. $141 3 payments
  11. Other $406 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,872 55 payments
  2. Consulting Fee $500 1 payment
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $584 4 payments
  2. CT THROMBECTOMY SYSTEM KIT $584 4 payments
  3. PULSERIDER $500 1 payment
  4. Pipeline $286 8 payments
  5. NEUROFORM ATLAS $187 2 payments
  6. SOMATOM go.Top $170 1 payment
  7. MAGNETOM Free.Max $170 1 payment
  8. WINGSPAN $149 1 payment
  9. LOBO $148 1 payment
  10. EMBOTRAP $147 2 payments
  11. Other $1,100 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Interventional Radiology: 38

Drug cost

$381

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 16 $381

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$87,927

Medicare's payments for the services billed

Medicare patients

156

Average age 78

Services billed

555

88 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 39%
Ischemic heart disease 39%
Atrial fibrillation 34%
Chronic kidney disease 29%
Heart failure 26%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record